| 陈华林,杨东红,罗怡平,刘美莲,李姝君,吴爱兵,杨志雄.埃克替尼联合化疗治疗EGFR突变型晚期非小细胞肺癌的疗效及对生活质量和血清肿瘤标志物的影响[J].,2021,(6):1138-1142 |
| 埃克替尼联合化疗治疗EGFR突变型晚期非小细胞肺癌的疗效及对生活质量和血清肿瘤标志物的影响 |
| Effect of Icotinib Combined with Chemotherapy on Quality of Life and Serum Tumor Markers in Patients with EGFR Mutant Advanced Non-small Cell Lung Cancer |
| 投稿时间：2020-09-08 修订日期：2020-09-30 |
| DOI：10.13241/j.cnki.pmb.2021.06.031 |
| 中文关键词: 疗效 化疗 晚期非小细胞肺癌 埃克替尼 生活质量 表皮生长因子受体突变型 肿瘤标志物 毒副反应 |
| 英文关键词: Icotinib Chemotherapy Epidermal growth factor Advanced non-small cell lung cancer Efficacy Quality of life Tumor markers Toxic and side effects |
| 基金项目:广东省科技计划项目（2016A020215228）；广东省湛江市科技发展专项资金竞争性分配项目（2018A010220） |
|
| 摘要点击次数: 963 |
| 全文下载次数: 719 |
| 中文摘要: |
| 摘要 目的：观察表皮生长因子受体（EGFR）突变型晚期非小细胞肺癌（NSCLC）经化疗联合埃克替尼治疗后的临床效果。方法：122例研究对象均为我院于2015年3月~2019年3月期间收治的晚期NSCLC患者且为EGFR突变型。采用随机数字表法将患者分为对照组（单药埃克替尼靶向药物治疗）和实验组（埃克替尼联合化疗），各61例。观察两组疗效、生活质量、血清肿瘤标志物、毒副反应的变化，比较两组患者的无进展生存期（PFS）和总生存期（OS）。结果：实验组治疗后的客观缓解率、疾病控制率均高于对照组（P<0.05）。实验组治疗后整体生活质量和健康状况总得分高于对照组，功能及症状总得分低于对照组（P<0.05）。实验组治疗后癌胚抗原（CEA）、癌抗原125（CA125）与角蛋白19片段（CYFRA21-1）低于对照组（P<0.05）。实验组毒副反应总发生率高于对照组（P<0.05）。两组间PFS、OS生存率比较均有统计学差异（P<0.05）。结论：埃克替尼联合化疗治疗EGFR突变型晚期NSCLC患者疗效较好，可有效阻止疾病进展，提高患者生活质量，改善患者预后。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the clinical effect of epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC) after chemotherapy combined with icotinib. Methods: 122 patients with EGFR mutant advanced NSCLC in our hospital from March 2015 to March 2019 were selected. The patients were randomly divided into control group(single drug icotinib targeted drug therapy) and experimental group (icotinib combined with chemotherapy) by random number table method, 61 cases each. The efficacy, quality of life, serum tumor markers and toxic and side effects of the two groups were observed, and the progression free survival (PFS) and overall survival (OS) of the two groups were compared. Results: The objective remission rate and disease control rate of the experimental group after treatment were higher than those of the control group (P<0.05). After treatment, the total scores of quality of life and health status in the experimental group were higher than those in the control group, while the total scores of function and symptoms in the experimental group were lower than those in the control group (P<0.05). After treatment, carcinogenic antigen 125 (CA125), carcinoembryonic antigen (CEA) and keratin 19 fragments (CYFRA21-1) in the experimental group were lower than those in the control group (P<0.05). The total incidence of toxic reactions in the experimental group was higher than that in the control group (P<0.05). PFS and OS survival rates were significantly different between the two groups (P<0.05). Conclusion: Icotinib combined with chemotherapy has a good effect on patients with advanced EGFR mutant NSCLC, which can effectively prevent disease progression, improve patients' quality of life, and improve patients' prognosis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
